Cargando…

New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19). The outbreak of this coronavirus was first identified in Wuhan (Hubei, China) in December 2019, and it was declared as pandemic by the World Health Organization (WHO) in March 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bauso, Luana Vittoria, Imbesi, Chiara, Irene, Gasparo, Calì, Gabriella, Bitto, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228036/ https://www.ncbi.nlm.nih.gov/pubmed/34070359 http://dx.doi.org/10.3390/ph14060503

Ejemplares similares

Clinical Trials of Repurposed Antivirals for SARS-CoV-2
por: Martinez, Miguel Angel
Publicado: (2020)

Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach
por: Gangadharan, Sivakumar, et al.
Publicado: (2022)

Applying polypharmacology approach for drug repurposing for SARS-CoV2
por: Jamir, Esther, et al.
Publicado: (2022)

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2
por: Pizzorno, Andrés, et al.
Publicado: (2020)

Computational guided approach for drug repurposing against SARS-CoV-2
por: Anand, Jigisha, et al.
Publicado: (2021)

Drug repurposing against SARS-CoV-2 using computational approaches
por: Kumar, Sumit, et al.
Publicado: (2022)

A deep learning ensemble approach to prioritize antiviral drugs against novel coronavirus SARS-CoV-2 for COVID-19 drug repurposing
por: K., Deepthi, et al.
Publicado: (2021)

What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2?
por: Martinez, Miguel Angel
Publicado: (2022)

Computational target-based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS-CoV-2 proteins
por: Balasubramaniam, Meenakshisundaram, et al.
Publicado: (2020)

In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins
por: Maffucci, Irene, et al.
Publicado: (2020)

Pharmacophore Modelling-Based Drug Repurposing Approaches for SARS-CoV-2 Therapeutics
por: Rampogu, Shailima, et al.
Publicado: (2021)

Computational approaches for drug repositioning and repurposing to combat SARS-CoV-2 infection
por: Panda, Subhamay, et al.
Publicado: (2022)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

L1000 connectivity map interrogation identifies candidate drugs for repurposing as SARS-CoV-2 antiviral therapies
por: Sendama, Wezi
Publicado: (2020)

Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing
por: Fidan, Ozkan, et al.
Publicado: (2022)

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease
por: Baker, Jeremy D., et al.
Publicado: (2021)

In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021)

Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
por: Patocka, Jiri, et al.
Publicado: (2021)

A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2
por: Simonis, Alexander, et al.
Publicado: (2020)

Phospholipidosis is a shared mechanism underlying the in vitro antiviral activity of many repurposed drugs against SARS-CoV-2
por: Tummino, Tia A., et al.
Publicado: (2021)

The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing
por: Hu, Xuqiao, et al.
Publicado: (2021)

Molecular targets and system biology approaches for drug repurposing against SARS-CoV-2
por: Singh, Rahul Kunwar, et al.
Publicado: (2020)

Multi-Targeted Approaches and Drug Repurposing Reveal Possible SARS-CoV-2 Inhibitors
por: Alanazi, Khalid Mashay, et al.
Publicado: (2021)

Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2
por: Tummino, Tia A., et al.
Publicado: (2021)

Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity
por: Barsi, Szilvia, et al.
Publicado: (2022)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

Tackling SARS-CoV-2: proposed targets and repurposed drugs
por: Joshi, Siddhi, et al.
Publicado: (2020)

Anti-HIV drug repurposing against SARS-CoV-2
por: Sang, Peng, et al.
Publicado: (2020)

Drug repurposing for SARS-CoV-2 (COVID-19) treatment
por: Mtewa, Andrew G., et al.
Publicado: (2022)

Improved and optimized drug repurposing for the SARS-CoV-2 pandemic
por: Cohen, Sarel, et al.
Publicado: (2023)

Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system
por: Punekar, Madhura, et al.
Publicado: (2022)

FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms
por: Ahmed, Mahmoud S., et al.
Publicado: (2023)

Structural Homology-Based Drug Repurposing Approach for Targeting NSP12 SARS-CoV-2
por: Aljuaid, Abdulelah, et al.
Publicado: (2022)

In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach
por: Zapata-Cardona, Maria I., et al.
Publicado: (2023)

Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing
por: Sadegh, Sepideh, et al.
Publicado: (2020)

Antiviral drugs against SARS-CoV-2
por: Aiello, Tommaso Francesco, et al.
Publicado: (2022)

Understanding SARS‐CoV‐2 endocytosis for COVID‐19 drug repurposing
por: Glebov, Oleg O.
Publicado: (2020)

Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor
por: Ahsan, Tamim, et al.
Publicado: (2021)

Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing
por: Kern, Charlotte, et al.
Publicado: (2021)

Potential repurposed SARS-CoV-2 (COVID-19) infection drugs
por: Abuo-Rahma, Gamal El-Din A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aafog95mgd7pj0ih31l8ivrrpk